Skip to main content

Table 1 Characteristics of 53 patients treated with the triplet chemotherapy regimen

From: Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer

Median age (range) (y) 52 (23–74)
Male/female [number (%)] 29 (55)/24 (45)
ECOG performance status [number (%)]
 0 7 (13)
 1 35 (66)
 2 11 (21)
Primary tumor site [number (%)]
 Colon 23 (40)
 Rectosigmoid 21 (36)
 Rectum 9(15)
Prior surgery for primary tumor [number (%)] 29 (55)
Prior adjuvant chemotherapy [number (%)] 6 (11)
Prior radiotherapy [number (%)] 0
Number of metastasis sites [number (%)]
 Single 22 (42)
 Multiple sites 31 (58)
Metastasis sites [number (%)]
 Liver 35 (66.0)
 Lung 22 (41.5)
 Lymph nodes 21 (39.6)
 Peritoneum 14 (26.4)
K-ras [number (%)]
 Wild-type 20 (37.0)
 Mutated 20 (37.0)
 Unknown 13 (26.0)
  1. Y years